key: cord-0828914-135z8347 authors: Falleni, Monica; Tosi, Delfina; Savi, Federica; Chiumello, Davide; Bulfamante, Gaetano title: Endothelial-Mesenchymal Transition in COVID-19 lung lesions date: 2021-03-26 journal: Pathol Res Pract DOI: 10.1016/j.prp.2021.153419 sha: f43fbaba186364d6eac92cb82fe24592a4758d58 doc_id: 828914 cord_uid: 135z8347 Sars-Cov-2 infection is still a healthcare emergency and acute respiratory distress failure with Diffuse Alveolar Damage (DAD) features is the main causes of patients’ death. Pathogenic mechanisms of the disease are not clear yet, but new insights are necessary to improve therapeutic management, to prevent fatal irreversible multi-organ damage and to adequately follow up those patients who survive. Here we investigated, by histochemistry and immunohistochemistry, a wide number of mapped lung specimens taken from whole body autopsies of 7 patients dead of COVID-19 disease. Our data confirm morphological data of other authors, and enlarge recent reports of the literature suggesting that Endothelial–Mesenchymal Transition might be central to COVID-19 lung fibrosing lesions. Furthermore, based upon recent acquisition of new roles in immunity and vascular pathology of the CD31 molecule, we hypothesize that this molecule might be important in the development and treatment of COVID-19 pulmonary lesions. These preliminary findings need further investigations to shed light on the complexity of Sars-Cov-2 disease. In-depth analyses on pathomechanisms leading to Sars-Cov-2 patients' death are critical to appropriate therapeutic management of symptomatic subjects and to follow up those who survive. Aspects of Diffuse Alveolar Damage (DAD), often with thromboembolism and superimposed infections, were described in the lung tissue of COVID-19 deceased patients (1, 2) . Recently the Endothelial-Mesenchymal Transition (End-MT) process was suggested to have an important role in COVID-19 pulmonary fibrosis by Eapen et al. (3) . Here we investigated with histochemistry and immunohistochemistry lung specimens from whole body COVID-19+ autopsies to deepen aspects of the disease pathogenesis possibly useful to rationalize therapies. Whole body autopsies were performed in 7 consecutive COVID-19+ patients died of the disease in the Sub-Intensive and Intensive Care Unit of San Paolo Hospital, University of Milan, Italy (patients' clinical data are summarized in table 1). Autopsies were performed in safety within 1-2 hours from death to avoid post-mortem artefacts. Consecutive 3-µm sections from extensively mapped, routinely paraffin-embedded, lung tissue samples were explored by immunohistochemistry with the automatic immunostainer DAKO OMNIS (DAKO, Glostrup, Denmark). All lung samples were tested for Sars-Cov-V2 (2019-nCoV) Nucleoprotein (NP) antigen (Sino Biological) to confirm the virus presence (4). In order to assess tissue changes in epithelial and vascular lung architecture, we used Cytokeratin 7, TTF1, Napsin A, Vimentin, Calponin, α-Actin, Desmin, CD34, CD31 and ERG antibodies. Inflammatory background was characterized with antibodies against CD20, CD3, CD4, CD8, CD56, MUM1, CD15 and CD163. Parasites other than Sars-Cov-V2 virus were evaluated with Gram and PAS stains. For each patient, three areas with different stages of disease evolution (early, proliferative and fibrotic) were selected and 3 high power fields (X40) were evaluated in each area. For each marker, a semi-quantitative score (none = 0, mild = 1, moderate = 2, severe = 3) was applied as previously described (5), reporting the mean score value of each area (early, proliferative and fibrotic). Slides were simultaneously evaluated by all the pathologists of the study. Lung sections from 7 non COVID-19+ post-bacterial pneumonia with fibroblastic proliferations were used as controls. In all cases Sars-Cov-V-2 infection was documented by immunoreactivity for NP viral antigen in respiratory epithelium, pneumocytes, endothelium and inflammatory cells. GRAM stain was positive in two patients with overlapping infection. All patients, including that from Sub-Intensive Care Unit, had similar pulmonary microscopic aspects, with prevalent early/exudative and intermediate/proliferative phases of DAD and minimal collagen deposition. No differences in score values were observed among immune cell groups in DAD phases. Since early lung injury the inflammatory infiltrate was predominantly constituted by macrophages, diffusely detected in damaged parenchyma. Macrophages with unusual morphology (bi-nucleation and eosinophilic large nucleoli) and increased strong CD31 and CD163 immunoreactivity were mixed with hyperplastic atypical and sometimes metaplastic pneumocytes engulfing alveolar spaces. This aspect was present also in J o u r n a l P r e -p r o o f DAD proliferative phase, where their number still increased and a fibroblastic foci entrapment was evident. Only in the fibrosing phase macrophages began slightly to decrease, crushed by the fibrosis. Faint fibrotic modification in vessels are appreciable since early phases: weak blue collagen deposition around medium-sized vessels was accompanied with discontinuity in CD34 and, to a lesser extent, in CD31 immunostaining of capillaries. In areas with proliferative DAD aspects, fibroblastic foci, both as small plugs and elongated interlacing bundles of spindle cells, showed intermediate/high expression of α-Actin and CD31 in early lesions; in more advanced lesions, α-Actin displayed no modification while CD31 immunoreactivity decreased to loss when a concomitant cytoplasmic accumulation of slightly blue collagen material was appreciated. All cases showed damaged vascular network: in early lesions swollen endothelium in capillaries of alveolar septa showed discontinuous and reduced CD34, ERG and CD31 immunostaining. In fields with early proliferative DAD features small and medium-sized vessels exhibited homogenous eosinophilic thickened walls and narrowed lumen in close continuity with oval or spindle cells of fibroblastic foci; these cells were strongly positive to CD31 and showed intermediate immunoreactivity to α-Actin and Vimentin, with only a weak staining for Calponin. Fibroblastic spindle cells in proliferative DAD fields reduced CD31 staining, acquired strong immunoreactivity for Vimentin, Calponin and α-Actin, and were negative to ERG and CD34; their cytoplasm turned from red to blue with Masson's Trichrome, due to accumulation of collagenous material. In the most damaged lung fields (late proliferative/early fibrosing lesions), vessels were unrecognizable and spindle cells, with bluish cytoplasmic collagen with Masson staining, were negative to CD34, ERG and CD31. In control lungs fibrotic areas, endothelial markers (CD34, ERG and CD31) showed disruption but not reduction in the immunohistochemical expression. Results are depicted in figure 1 and 2 role in the process. This is particularly true considering that immune cell infiltrate in COVID-19+ lung parenchyma is peculiarly rich in alveolar macrophages with CD31 overexpression. Though this molecule is a well-known endothelial marker, it is also expressed by macrophages and other inflammatory cells (8, 9) with important roles in mediation of pro-and anti-inflammatory signalling, and immuno-tolerance (6, 9) , in leucocyte-leucocyte engagement and interaction (9) , and in immune J o u r n a l P r e -p r o o f cell proliferation, apoptosis and migration (8) . In macrophages, CD31 was reported to be involved in the promotion of reparative polarized functions (10) and, interestingly, in this work, a cooverexpression of this antigen with CD163, a M2 macrophage molecule associated to tissue remodelling and repair, was found in these cells. All Authors have seen and approved the final version of the manuscript being submitted. They warrant that the article is the authors' original work, hasn't received prior publication and isn't under consideration for publication elsewhere. The Authors declare no conflicts of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. For Each marker, the mean values of scores attributed to 3 different areas representative of each evolutionary phase in patients' slides are here reported. No important differences were found among inflammatory cells but macrophages, which accumulated with disease progression. CD31 was progressively lost (as ERG) by vessels near fibroblastic foci, but its expression increased in macrophages in evolving lesions (*) (see text and figures). Marker Exudative/Early Proliferative/ Intermediate Fibrosing/ Late Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration? Evidence of SARS-CoV-2 Transcriptional Activity in Cardiomyocytes of COVID-19 Patients without Clinical Signs of Cardiac Involvement Tissue-Specific Immunopathology in Fatal COVID-19 Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis CD31 regulates metastasis by inducing epithelialmesenchymal transition in hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway An immunologist's guide to CD31 function in T-cells Macrophage CD31 Signaling in Dissecting Aortic Aneurysm Mechanisms for the Resolution of Organ Fibrosis SARS-CoV-2 and viral sepsis: observations and hypotheses We would like to thank all the staff members of the Pathology lab for the diligence, technical skills and willingness spent in this research.